Antihistamine plus immunotherapy: a new hope for lung cancer patients?
NCT ID NCT07358689
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding the antihistamine diphenhydramine to the immunotherapy drug toripalimab and standard chemotherapy helps shrink tumors more effectively in people with operable non-small cell lung cancer. About 120 participants will receive either the combination or just toripalimab plus chemo before and after surgery. The main goal is to see how many patients have no cancer cells left in their removed tumor tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (a PD-1 inhibitor) and diphenhydramine (an antihistamine) plus platinum-based chemotherapy
- What this could lead to
- If successful, this could point toward a more effective pre-surgery treatment for lung cancer that helps shrink tumors more completely.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to all patients. Adding diphenhydramine could also increase side effects without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- New drug combo aims to shrink tough lung tumors
- New drug combo aims to outsmart lung cancer that resists immunotherapy
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation
- Lung cancer drug interaction study aims to uncover safe dosing